
Celebrating Little Victories
Lung cancer survivor Denise Swick reflects on a year of ups and downs as she went through treatment.
College of Medicine
At the forefront of cancer research, the MUSC Hollings Cancer Center (HCC) is one of 72 National Cancer Institute-designated cancer centers in the nation and the only one in South Carolina. This research is the driving force behind delivering medical advances to patients and their families, enabling us to educate health care professionals and the public and to establish outreach services for underserved populations across the state.
As an integral component of the Hollings Cancer Center, the MUSC Division of Hematology & Oncology builds upon a long history of excellence in hematology and hematological malignancies, as well as solid tumor oncology and bone marrow transplant. Division faculty are leaders in the fields of cancer care and blood disorders. In the latest rankings by U.S. News & World Report, MUSC Health's Hematology/Oncology program ranked as high-performing for the treatment of cancer.
The division’s fellowship program continues to recruit top tier candidates and is the only hematology oncology training program in the state of South Carolina. The program provides each fellow extensive clinical training in outpatient, inpatient, and consultative medical oncology and benign and malignant hematology, including autologous and allogeneic stem cell transplantation.
Learn more about our Hematology & Oncology Fellowship Program
Our faculty lead pioneering research and clinical trials, expanding treatment options for cancers and blood disorders. As an NCI-Designated Cancer Center, Hollings offers exclusive therapies and trials unavailable elsewhere in South Carolina.
Learn more about our Research Program
As a statewide referral center, our division specializes in solid tumor oncology, malignant and benign hematology, and bone marrow transplants. With a dedicated clinical team, we provide exceptional care at Hollings Cancer Center, the Ralph H. Johnson VA Medical Center, Medical University Hospital, and Ashley River Tower.
The Blood and Bone Marrow Transplant team recently celebrated 3,000 transplants – and patient Kennedy Golden exemplifies why they do what they do.
A clinical trial of CAR-T cell therapy developed at Hollings has received NCI funding to expand.